News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 11, 2020, 13:07 ET AbbVie Announces New Formulary Listings for SKYRIZI® in the Treatment of Moderate to Severe Plaque Psoriasis

SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe psoriasis.1 In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16...


Dec 06, 2019, 06:00 ET AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Psoriasis is a chronic condition affecting 125 million people worldwide and many patients despite treatment still do not reach their goals or lose treatment response over time. 1-3 SKYRIZI™ is a...


Nov 20, 2019, 08:00 ET Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie (NYSE: ABBV), a research-based global ...


Sep 25, 2019, 09:00 ET VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada

MONTREAL, Sept. 25, 2019 /CNW/ - AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Alberta, Manitoba, British Columbia and Saskatchewan are...


Jun 25, 2019, 09:00 ET AbbVie Receives Positive Recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With

INESSS recommends the reimbursement of VENCLEXTA® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL).i Adult patients with CLL...


Jun 10, 2019, 08:00 ET AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1 MAVIRET is the only...


Jun 06, 2019, 09:00 ET AbbVie Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic

pERC conditionally recommends reimbursement of VENCLEXTA® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at...


May 30, 2019, 08:00 ET AbbVie's MAVIRET™ now listed in New Brunswick

MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1 MAVIRET is the only...


May 23, 2019, 09:00 ET AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)

Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse VENCLEXTA. VENCLEXTA is the first and only BCL-2...


May 21, 2019, 08:00 ET AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

Endometriosis affects up to one in 10 women of reproductive age in Canada.1 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month.2 MONTREAL, May 21, 2019 /CNW/...


Apr 18, 2019, 10:04 ET Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

SKYRIZI™(risankizumab) is a novel, humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit to treat moderate to severe plaque psoriasis1 ....


Apr 11, 2019, 09:00 ET AbbVie's MAVIRET™ now reimbursed in Quebec

MAVIRET is now listed under the "Régie de l'assurance maladie du Québec" List of Medications. MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus ...


Apr 04, 2019, 10:00 ET AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

Alberta, Saskatchewan and the Non-Insured Health Benefits (NIHB) Program list MAVIRET on their formularies MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C...


Mar 22, 2019, 10:29 ET British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRET™ on its Formulary

British Columbia PharmaCare lists MAVIRET on its formulary effective March 21, 2019 MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis...


Feb 21, 2019, 12:09 ET AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™

Ontario will be the first province to reimburse MAVIRET as of February 28, 2019 MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and...


Nov 07, 2018, 17:40 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV

Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) and certain of its officers. The class action, filed in United States...


Oct 15, 2018, 07:00 ET Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed

Updated label provides guidance that HUMIRA use can be considered while breastfeeding and should only be used during pregnancy if clearly needed1 Approval is supported by postmarketing data, a...


Oct 25, 2017, 08:00 ET Nail psoriasis data now part of HUMIRA® label

80% of patients with plaque psoriasis may develop nail psoriasis in their lifetime Over 50% of moderate to severe psoriasis patients suffer from nail disease Psoriasis patients with nail involvement...


Feb 01, 2017, 08:00 ET Health Canada Grants Priority Review to AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis AbbVie's New Drug Submission is supported by data...


Dec 09, 2016, 08:00 ET Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA™ (Daclizumab Beta) for Multiple Sclerosis

Approval Supported by Largest and Longest Head-to-Head Global Phase 3 Study Conducted in Multiple Sclerosis (MS) ZINBRYTA™ Significantly Reduced Multiple Measures of Disease Activity in Patients with ...


Oct 05, 2016, 08:00 ET AbbVie's New Oral Therapy VENCLEXTA™ Now Available For Canadians With A Difficult-To-Treat Blood Cancer

AbbVie, a global biopharmaceutical company, today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for VENCLEXTA™ (venetoclax). The therapy has been approved for...


Jan 06, 2016, 07:00 ET AbbVie's HUMIRA® (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease MONTREAL, Jan. 6, 2016 /CNW/ - AbbVie, a global biopharmaceutical company, today announced that Health Canada approved...


Dec 09, 2015, 09:00 ET AbbVie's HUMIRA® (adalimumab) receives Health Canada approval for the extension of the Polyarticular Juvenile Idiopathic Arthritis indication for patients between 2 and 4 years

Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 per cent of all JIA patients1 HUMIRA was approved in Canada in 2012 for moderate to severe polyarticular JIA in patients...


Nov 24, 2015, 07:00 ET AbbVie's TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection

TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically considered difficult–to-treat...


Nov 18, 2015, 08:00 ET AbbVie renews commitment to Structural Genomics Consortium

Contributes $7.5 million for five-year partnership MONTREAL, Nov. 18, 2015 /CNW/ - AbbVie today announced its continued commitment to the Structural Genomics Consortium (SGC) by providing a cash...